Selective cell death-inducing enzyme system
AssigneeSIT Biotech GmbH
InventorsSylvain TOUREL, Tabea KRÄFT
Life of this patent
Estimating the term…
Abstract
The invention relates to a fusion protein containing a selective cell death-inducing enzyme system for use in the therapy and/or treatment of cancer and tumors in humans and animals, a process, and its use.
Claims12
A drug for use in the treatment of cancer or tumor diseases containing a fusion protein comprising at least one sequence selected from the group of
- SEQ ID no. 9, 10 derived from caspase 3 and/or
- SEQ ID no. 11, 12 derived from caspase 7 and/or
- SEQ ID no. 13, 14 derived from caspase 8 and/or
- SEQ ID no. 15, 16 derived from caspase 10 and/or
- or a nucleic acid encoding it, or a functional variant of either,
- and
- at least one tobacco etch virus protease or a nucleic acid encoding it or a functional variant of either, and
- at least one recognition site ENLYFQS (SEQ ID no. 3) or ENLYFQG (SEQ ID no. 4) or a nucleic acid encoding it
- characterized in that
- the SEQ ID no. SEQ ID no. 9, 10, 11, 12, 13, 14, 15 or 16 or a functional variant of it is released by means of cleavage by tobacco etch virus protease.
A drug for use in the treatment of cancer or tumor diseases according to one of the preceding claims, characterized in that it is administered by means of a gene therapy process.
A drug for use in the treatment of cancer or tumor diseases according to one of the preceding claims, characterized in that this gene therapy process is carried out by means of a vehicle.
A drug for use in the treatment of cancer or tumor diseases according to one of the preceding claims, characterized in that this vehicle is selected from the group of liposomes, nano- or microparticles, viruses, and lipoplexes.
A drug for use in the treatment of cancer or tumor diseases according to one of the preceding claims, characterized in that these vehicles contain ligands that recognize tumor markers.
A process for introducing a drug as described in one of the preceding claims, wherein an inactive form of caspase 3 and/or caspase 7 and/or caspase 8 and/or caspase 10 comprising a nucleic acid encoding SEQ ID no. 5, 6, 7 or 8, and a nucleic acid encoding tobacco etch virus protease (e.g., SEQ ID no. 1 or SEQ ID no. 2),
- especially an inactive form of caspase 3 and/or caspase 7 and/or caspase 8 and/or caspase 10 comprising a nucleic acid encoding a fusion protein comprising at least one sequence selected from the group of SEQ ID no. 9, 10, 11, 12, 13, 14, 15 or 16 and ENLYFQS (SEQ ID no. 3) or ENLYFQG (SEQ ID no. 4) and a nucleic acid encoding tobacco etch virus protease,
- i.) are introduced in at least one vehicle,
- ii.) into a tumor cell and expressed there,
- iii.) producing an active form of caspase 3 and/or caspase 7 and/or caspase 8 and/or caspase 10 and inducing cell death in the tumor cell.
Dependencies are inferred from the claim text.